Integrated Computational Heart Model for Virtual Clinical Trials
Market Maturity: Tech Ready
These are innovations that are progressing on technology development process (e.g. pilots, prototypes, demonstration). Learn more
Market Creation Potential
This innovation was assessed by the JRC’s Market Creation Potential indicator framework as having a “High” level of Market Creation Potential. Only innovations that are showing multiple signals of market creation potential are assigned a value under this indicator system. Learn more
A woman had a leadership role in developing this innovation in at least one of the Key Innovator organisations listed below.
Go to Market needs
Needs that, if addressed, can increase the chances this innovation gets to (or closer to) the market incude:
Prepare for Market entry
Scale-up market opportunities
Location of Key Innovators developing this innovation
Steinbeis Advanced Risk Technologies GmbH
STUTTGART, DE Small or Medium Enterprise
UNIVERZA V LJUBLJANI
LJUBLJANA, SI Higher Education Institute / Research Centre
The EU-funded Research Project
This innovation was developed under the Horizon 2020 project SILICOFCM with an end date of 30/11/2021
According to the 2014 European Society of Cardiology Guidelines, cardiomyopathies are defined as structural and functional abnormalities of the ventricular myocardium that are unexplained by flow limiting coronary artery disease or abnormal loading conditions. There are four major classifications of cardiomyopathy: hypertrophic (HCM), dilated (DCM), restrictive (RCM), and arrhythmogenic right ventricular (ARVC).
Familial cardiomyopathies (FCM) are most commonly diagnosed, or progress of the disease is monitored, through in vivo imaging, with either echocardiography or, increasingly, cardiac magnetic resonance imaging (MRI). The treatment of symptoms of FCM by established therapies could only in part improve the outcome, but novel therapies need to be developed to affect the disease process and time course more fundamentally.
SILICOFCM project will develop in silico computational cloud platform which will integrate from stopped-flow molecular kinetic assays to magnetic resonance imaging of the whole heart, bioinformatics and image processing tools with state of the art computer models with the aim to reduce animal and clinical studies for a new drug development and optimized clinical therapy of FCM.
The developed system will be distributed on the cloud platforms in order to achieve efficient data storage and high-performance computing, that can offer end users results in reasonably short time. Academic technical partners IIT, UOI, UL and BSC will be responsible for developing and integration of in silico cloud computational platform with multi-scale cardiac muscle modelling which include experiments on protein mutation in vitro from UNIKENT, UNIFI and UW. Bioinformatics tools will be integrated by US company SBG. Clinical partners UNEW, ICVDV, UPMC and UHREG will do retrospective and prospective studies. SME partner R-Tech will be in charge of regulatory issues and reports and BIOIRC will do the exploitation of the project.
Innnovation Radar's analysis of this innovation is based on data collected on 27/07/2019.